CervoMed's Neflamapimod to Highlight Biomarker Results at ISFTD Meeting

CervoMed Inc, a clinical-stage biotechnology company focused on developing treatments for age-related brain disorders, announced that its investigational drug, neflamapimod, will be featured in a late-breaking oral presentation at the upcoming International Society of Frontotemporal Dementias (ISFTD) Annual Meeting. The presentation will highlight initial results from a 12-week clinical trial of neflamapimod in nonfluent variant primary progressive aphasia (nfvPPA).

The trial, which enrolled 25 participants, was designed to evaluate the safety, pharmacokinetics, and clinical effects of neflamapimod in patients with nfvPPA, a type of frontotemporal dementia (FTD) most commonly associated with tau pathology. The 12-week biomarker data from the first eight participants will be presented, focusing on two plasma biomarkers: neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP). The presentation will include findings from at least 22 study participants.

Neflamapimod is an oral, small molecule drug that targets the critical disease processes underlying degenerative brain disorders. Specifically, it selectively inhibits the alpha isoform of p38 MAP kinase, a key driver of neuroinflammation and synaptic dysfunction. The drug has shown potential to treat FTD driven by tau pathology and has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression.

The trial, titled "Initial Biomarker Results from a Phase 2a Clinical Trial of Neflamapimod in Patients with Nonfluent Variant Primary Progressive Aphasia (NCT07033481)," will take place during Plenary 6 (Hot Topics) of the ISFTD Annual Meeting in Philadelphia, Pennsylvania, on October 11, 2026, from 8:30 a.m. to 10:30 a.m. Eastern Time.

Nonfluent variant primary progressive aphasia, a subtype of FTD, affects an estimated 10,000 to 15,000 people in the United States and 15,000 to 20,000 people in the European Union. Currently, there are no approved treatments for nfvPPA in either region. The presentation at ISFTD underscores the potential of neflamapimod to address the unmet medical need in this patient population.

CervoMed Inc, headquartered in Boston, Massachusetts, continues to advance its drug development pipeline, with neflamapimod currently in clinical trials for the treatment of dementia with Lewy bodies (DLB) and nonfluent variant primary progressive aphasia. The company has also recently completed enrollment in its ongoing Phase 2a clinical trial evaluating neflamapimod in nfvPPA and is focused on identifying a strategic partner to advance the drug into a Phase 3 trial in DLB.

The ISFTD Annual Meeting is a significant forum for researchers and clinicians to discuss the latest advancements in frontotemporal dementia. The acceptance of CervoMed's abstract for a late-breaking oral session highlights the potential of neflamapimod to contribute to the understanding and treatment of this debilitating condition.